R&D News | pharmaphorum

News

AZ confirms its China president is under investigation

The head of AstraZeneca's Chinese operations has been placed under investigation by the authorities in Beijing, although the reasons for the probe remain unclear.

News

Eledon drug helps transplants 'cure' type 1 diabetes

Eledon Pharmaceuticals has revealed that two patients with type 1 diabetes achieved a 'functional cure' after receiving a transplant of insulin-producing islet cells in combination with its

News

Lilly touts new Kisunla regimen that reduces side effects

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions f

News

Pfizer rebuffs Starboard criticism as it raises forecasts

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist investor for complaining about the company's direction without c

News

AbbVie gets bigger in Alzheimer's R&D with Aliada takeover

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing.

News

Novartis pays $150m upfront for Monte Rosa degrader drug

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion.

AZ confirms its China president is under investigation

Eledon drug helps transplants 'cure' type 1 diabetes

Lilly touts new Kisunla regimen that reduces side effects

Pfizer rebuffs Starboard criticism as it raises forecasts

AbbVie gets bigger in Alzheimer's R&D with Aliada takeover

Novartis pays $150m upfront for Monte Rosa degrader drug

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks